Replies to post #857 on Rezolute Inc. (RZLT)

[Whalatane]

I also look at insider buys ....especially relevant after the pediatric trial " failure " ...and compare to other biotechs

Comparison of Management Insider Buys (Dec 2025 – Feb 2026)
The table below compares the number of individual management members (Officers/Directors) who made purchases, rather than just the total number of transactions.
Company Unique Management Buyers Key Roles Participating Total Management Shares
Rezolute (RZLT) 5 CEO, CFO, CMO, CCO, Director ~176,248
Oncolytics (ONCY) 3 CEO, CFO, Director ~147,100
MAIA Biotech (MAIA) 2+ CEO, Director ~182,445
Alumis (ALMS) 1 Director (multiple buys) 262,027
Zenas Bio (ZBIO) 1 Director 19,860
Analysis of Rezolute's Cluster
Breadth of Participation:
RZLT's buying is notable for its breadth across the entire C-suite (CEO, CFO, CMO, and CCO). This level of multi-executive alignment is rarer than large purchases by a single wealthy director or founder (as seen in Alumis).
Conviction vs. Volume:
While Alumis saw a higher dollar value ($2.04 million) and share count from a single director, Rezolute's 14.78% total insider ownership following these buys reflects a higher management stake compared to Alumis's 0.6%.
Timing:
RZLT management bought within 4 days of a 90% stock crash, signaling an immediate and collective attempt to stabilize investor sentiment.

So from this Gemini search since Dec 1st ...RZLT has the highest number of management making open market purchase .

By the way ...Stumble is in MAIA also . I'm not for the reasons laid out on that board

Kiwi